Gadolinium Deposition and Liver MRI

Marks, Robert M.; Ash, Ryan; Lee, James T.

doi:10.1002/cld.1024

Cited by 2 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14,15 Unfortunately, there has recently been concern over the use of GBCAs because of their long-term toxicity, especially their deposition in the kidney and brain. 16 However, it is still challenging to develop a more specific MRI agent for assessing the early phase of hepatocarcinogenicity.…”

Section: ■ Introductionmentioning

confidence: 99%

“…However, much effort has to be made to overcome sensitivity, specificity, method limitations, and technical considerations . Among the modalities, MRI with gadolinium-based contrast agents (GBCAs) has shown potential to stratify the early phase of hepatocarcinogenesis (e.g., dysplastic lesion) from eHCC and advanced HCC. , Unfortunately, there has recently been concern over the use of GBCAs because of their long-term toxicity, especially their deposition in the kidney and brain . However, it is still challenging to develop a more specific MRI agent for assessing the early phase of hepatocarcinogenicity.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Early Detection of Hepatocarcinogenicity in Rats Using MRI with Ferric–Tannic Nanoparticles

et al. 2023

View full text Add to dashboard Cite

Herein, we present molecular nanoparticles of ferric–tannic complexes (so called ferric–tannic nanoparticles, FT NPs) used to enhance the MRI signal in the early stage of hepatocarcinoma. FT NPs were found to accumulate in the hepatic parenchyma without tumor nodules of Wistar rats in which hepatocarcinogenicity had been induced using diethylnitrosamine (DEN). The MRI enhancement and accumulation of FT NPs were clearly observed in the early phase of hepatocarcinogenicity, which was possibly modulated by various solute carrier family members present in the entire hepatic parenchyma of the DEN-induced rats. These findings suggest that MRI with FT NPs is promising for the assessment of the early stage of hepatocarcinoma.

show abstract

Section: ■ Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Early Detection of Hepatocarcinogenicity in Rats Using MRI with Ferric–Tannic Nanoparticles

et al. 2023

View full text Add to dashboard Cite

show abstract

Gadolinium: pharmacokinetics and toxicity in humans and laboratory animals following contrast agent administration

Davies¹,

Siebenhandl-Wolff²,

Tranquart³

et al. 2022

Arch Toxicol

View full text Add to dashboard Cite

Gadolinium-based contrast agents (GBCAs) have transformed magnetic resonance imaging (MRI) by facilitating the use of contrast-enhanced MRI to allow vital clinical diagnosis in a plethora of disease that would otherwise remain undetected. Although over 500 million doses have been administered worldwide, scientific research has documented the retention of gadolinium in tissues, long after exposure, and the discovery of a GBCA-associated disease termed nephrogenic systemic fibrosis, found in patients with impaired renal function. An understanding of the pharmacokinetics in humans and animals alike are pivotal to the understanding of the distribution and excretion of gadolinium and GBCAs, and ultimately their potential retention. This has been well studied in humans and more so in animals, and recently there has been a particular focus on potential toxicities associated with multiple GBCA administration. The purpose of this review is to highlight what is currently known in the literature regarding the pharmacokinetics of gadolinium in humans and animals, and any toxicity associated with GBCA use.

show abstract

Gadolinium Deposition and Liver MRI

Cited by 2 publications

References 18 publications

Early Detection of Hepatocarcinogenicity in Rats Using MRI with Ferric–Tannic Nanoparticles

Early Detection of Hepatocarcinogenicity in Rats Using MRI with Ferric–Tannic Nanoparticles

Gadolinium: pharmacokinetics and toxicity in humans and laboratory animals following contrast agent administration

Contact Info

Product

Resources

About